Safety and Activity of HF50 in Patients With Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of HF50 in Patients With Advanced Solid Tumors
A study to assess the safety, tolerability, and pharmacokinetics of HF50 in participants with advanced solid tumors.
研究概览
详细说明
This is an open-label, dose-escalation and dose-expansion, multiple-dose, phase 1 study evaluating HF50 monotherapy in participants with advanced solid tumors. HF50 is an innovative liposome-encapsulated T-cell engager designed to redirect T-cells to tumor cells by presenting both tumor-associated antigen (e.g., HER2) and CD3 targeting moieties on the liposome surface. Simultaneously, HF50 delivers an encapsulated TLR7/8 agonist to activate innate immunity and remodel the tumor immune microenvironment, creating a synergistic anti-tumor immune response.The primary objective is to evaluate the safety and tolerability of HF50 and to determine the recommended Phase 2 dose (RP2D). HF50 will be administered as an intravenous (IV) infusion. The study will also assess the pharmacokinetic (PK) profile, immunogenicity, and preliminary anti-tumor activity of HF50. Additionally, the study will explore the impact of HF50 on the immune microenvironment and changes in peripheral blood cytokines and immune cells to better understand its biological effects.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:xun Wang
- 电话号码:+86-571-86961869
- 邮箱:wangxun717416@gmail.com
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100021
- 尚未招聘
- Cancer Hospital, Chinese Academy of Medical Sciences
-
接触:
- FEI MA, MD,PhD
-
首席研究员:
- FEI MA, MD,PhD
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510120
- 招聘中
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
-
首席研究员:
- Jing Li, MD, PhD
-
首席研究员:
- Qiong Yang, MD, PhD
-
接触:
- HERUI YAO, MD,PhD
- 电话号码:+8613500018020
- 邮箱:yaohrsysu@163.com
-
首席研究员:
- HERUI YAO, MD,PhD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Voluntary participation: Capable of giving signed informed consent and able to comply with all study-related procedures.
- Age: Adults >= 18 years of age at the time of signing informed consent; male or female.
- Disease Status: Participants with histologically or cytologically confirmed advanced solid tumors that are unresectable or metastatic, who have failed or are intolerant to standard therapies, or for whom no effective therapy currently exists. Examples include HER2-expressing gynecological tumors and recurrent ovarian clear cell carcinoma after failure of platinum-based chemotherapy.
- Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
- Life Expectancy: Anticipated survival of no less than 6 months.
- Measurable Disease: At least one measurable lesion according to RECIST v1.1 definitions.
- Organ and Bone Marrow Function:
Bone Marrow Reserve: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L, lymphocyte count >= 1.0 x 10^9/L, platelet count >= 90 x 10^9/L, and hemoglobin >= 9.0 g/dL (no blood transfusion or hematopoietic stimulators within 14 days).
Coagulation Function: Activated partial thromboplastin time (APTT) <= 1.5 x ULN, and International Normalized Ratio (INR) <= 1.5.
Liver Function: Total bilirubin (TBIL) <= 1.5 x ULN, and ALT and AST <= 2.5 x ULN. For participants with liver metastases: ALT and AST <= 5 x ULN, and TBIL <= 3 x ULN.
Renal Function: Creatinine clearance >= 50 mL/min (calculated using the Cockcroft-Gault formula).
- Contraception: Participants of reproductive potential (including males) must agree to use effective contraception from study entry through 6 months after the last dose. Female participants of childbearing potential must have a negative serum pregnancy test during screening and prior to the first dose.
Exclusion Criteria:
- Autoimmune Disease: Any active autoimmune disease or history of autoimmune disease deemed unsuitable by the investigator. Exceptions include skin conditions not requiring systemic treatment (e.g., eczema < 10% of body surface area, vitiligo, psoriasis, alopecia) and resolved childhood asthma.
- Corticosteroids/Immunosuppressants: Current use of immunosuppressants or systemic corticosteroids (> 10 mg/day prednisone or equivalent) within 4 weeks prior to the first dose. Topical steroid use is permitted.
- Prior Anti-tumor Therapy: Receipt of systemic chemotherapy, radiotherapy, targeted therapy, or immunotherapy within 2 weeks prior to dosing (4 weeks for nitrosoureas or mitomycin C); or other therapies (endocrine therapy, TCM, localized palliative radiotherapy) within 2 weeks.
- CNS Metastasis: Clinically symptomatic brain or meningeal metastases. Participants with treated brain metastases are eligible if radiographic stability is maintained for >= 28 days, systemic steroids have been discontinued for > 14 days, and the participant is asymptomatic.
- Toxicity Recovery: Failure to recover from all adverse events of prior therapies to <= Grade 1 (NCI CTCAE v5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, or stable hypothyroidism on hormone replacement.
- Cardiovascular History: Including thromboembolic events within 3 months; NYHA Class III to IV congestive heart failure; acute coronary syndrome, aortic dissection, stroke, or other Grade >= 3 cardiovascular events within 6 months; or uncontrolled hypertension (SBP > 160 mmHg or DBP > 100 mmHg).
- Infection: Active infection or unexplained fever > 38.5 degrees C within 1 week prior to the first dose (tumor-related fever is permitted per investigator judgment).
- Viral Infection: HIV infection, active HBV (HBV DNA > ULN), or active HCV (HCV RNA > ULN).
- Gastrointestinal Symptoms: Significant digestive system symptoms or other factors requiring intervention within 4 weeks prior to the first dose.
- Pregnancy/Lactation: Female participants who are pregnant or breastfeeding.
- Other: Any other serious systemic disease or reason that, in the investigator's opinion, makes the participant unsuitable for the study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:HF50
HF50 monotherapy |
HF50 is an innovative liposome-encapsulated bifunctional therapeutic designed to redirect T-cells to HER2-expressing tumor cells while simultaneously activating innate immunity through TLR7/8 agonism. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants with Dose Limiting Toxicities (DLT)
大体时间:28 days after the first dose (C1D1) for each dose cohort.
|
The number of participants experiencing dose-limiting toxicities (DLTs) during the DLT evaluation period to determine the maximum tolerated dose (MTD). |
28 days after the first dose (C1D1) for each dose cohort.
|
|
Incidence of Adverse Events (AEs)
大体时间:From first dose to 28 days after the last dose.
|
The number and percentage of participants experiencing adverse events (AEs), graded according to NCI-CTCAE v5.0 |
From first dose to 28 days after the last dose.
|
|
Recommended Phase II Dose (RP2D) of HF50
大体时间:At the end of dose escalation (assessed up to 1 year)
|
RP2D will be determined based on safety, tolerability, and pharmacokinetics data collected during the dose escalation phase. |
At the end of dose escalation (assessed up to 1 year)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective Response Rate (ORR)
大体时间:Up to 2 years
|
Proportion of participants achieving a complete response (CR) or partial response (PR) based on RECIST v1.1 criteria. |
Up to 2 years
|
|
Duration of Response (DOR)
大体时间:Up to 2 years
|
Time from the first documented response (CR or PR) to disease progression or death. |
Up to 2 years
|
|
Disease Control Rate (DCR)
大体时间:Up to 2 years
|
Proportion of participants achieving CR, PR, or stable disease (SD) based on RECIST v1.1. |
Up to 2 years
|
|
Progression-Free Survival (PFS)
大体时间:Up to 2 years
|
Time from the first dose to disease progression or death. |
Up to 2 years
|
|
Overall Survival (OS)
大体时间:Up to 2 years
|
Time from the first dose to death from any cause. |
Up to 2 years
|
|
Pharmacokinetic Parameter - Cmax
大体时间:Up to 2 years
|
Maximum plasma concentration (Cmax) of HF50 will be assessed following single and multiple dosing. |
Up to 2 years
|
|
Pharmacokinetic Parameter - Tmax
大体时间:Up to 2 years
|
Time to maximum plasma concentration (Tmax) of HF50 will be assessed following single and multiple dosing. |
Up to 2 years
|
|
Pharmacokinetic Parameter - AUC (Area Under the Curve)
大体时间:Up to 2 years
|
AUC0-t and AUC0-inf will be evaluated to determine systemic exposure to HF50. |
Up to 2 years
|
|
Pharmacokinetic Parameter - Half-life (t1/2)
大体时间:Up to 2 years
|
The terminal elimination half-life (t1/2) of HF50 will be calculated. |
Up to 2 years
|
合作者和调查者
调查人员
- 首席研究员:HERUI YAO, MD,PhD、Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- HF50-102
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.